NASDAQ · Medical Distribution · USD
Cellyan Biotechnology Co., Ltd (HKPD) Stock Analysis
Cellyan Biotechnology Co., Ltd (HKPD) is a Medical Distribution stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
HKPD Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.0898
- Previous Close
- $0.11
- Day's Range
- 0.0814–0.11
- 52-Week Range
- 0.0814–1.72
- Volume
- 2.87M
Valuation
- Market Cap
- $5.03M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.37
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.07
Financials (FY)
- Revenue (FY)
- $20.31M+21.72%
- Net Income (FY)
- −$27.06K−102.03%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −8.46%
- Shares Outstanding
- 42.17M
- 1-Year Return
- −91.36%
Dividend and dates
- Avg Volume
- 3.72M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, HKPD closed at $0.10, −91.36% over 1 year.
Cellyan Biotechnology Co., Ltd (HKPD) has a market capitalization of $5.03M.
In fiscal 2024, HKPD reported revenue of $20.31M.
HKPD Stock Return by Calendar Year
Cellyan Biotechnology Co., Ltd (HKPD) return since Jan 2025: what $10,000 became
- 1 year
- $10,000 $864
- −91.36%
- Since Jan 2025
- $10,000 $362
- −96.38%
If you had invested $10,000 in Cellyan Biotechnology Co., Ltd (HKPD) at the close on January 15, 2025, the earliest close on record here, it would have been worth $362 at the close on October 21, 2026: −96.38% in total, −84.78% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −87.62% |
| 2025 | −70.78% |
As of October 21, 2026.
HKPD Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $20.31M | −$27.06K | −0.1% |
| 2023 | $16.69M | $1.33M | 8.0% |
| 2022 | $12.56M | $998.20K | 7.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $20.31M | $2.42M | $200.77K | −$27.06K | −0.1% |
| 2023 | $16.69M | $3.56M | $1.67M | $1.33M | 8.0% |
| 2022 | $12.56M | $2.74M | $1.08M | $998.20K | 7.9% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2025.
HKPD Valuation vs Medical Distribution Median
Median of 11 stocks| Metric | HKPD | Medical Distribution median | vs median |
|---|---|---|---|
| P/S ratio | 0.37 | 0.38 | 2% below |
| Profit margin | −8.46% | −4.73% | 3.7 pts below |
Medians across 11 Medical Distribution stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Distribution Stocks
McKesson Corporation
$118.40B
CORCencora, Inc.
$64.96B
CAHCardinal Health, Inc.
$58.83B
HSICHenry Schein, Inc.
$9.47B
AHGAkso Health Group
$1.09B
FOCLEDAP TMS S.A.
$206.34M
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B